A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

5101

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Breast Cancer

Interventions

DRUG: Ribociclib
OTHER: Endocrine Therapy (ET)

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]